On November 2, 2015 ViroGin Biotech Ltd (ViroGin), an early stage biotech research company, reported a collaboration agreement with Johnson & Johnson Innovation and Janssen Biotech, Inc. ("Janssen") to further the development of ViroGin’s novel oncolytic therapeutics for the treatment of cancer (Press release, Virogin Biotech, NOV 2, 2015, View Source [SID1234518863]). Schedule your 30 min Free 1stOncology Demo! The collaboration agreement will leverage the resources of Johnson & Johnson Innovation, including scientific experts, to continue the development of ViroGin’s technology.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. William Jia, CSO of ViroGin said, "Our team has been developing oncolytic virotherapy since the 90s, including many years of study in Canada and the first oncolytic virotherapy clinical trial in China. Now, through our collaboration with Johnson & Johnson Innovation, we can leverage their global resources and scientific expertise to work together in China, the US, Canada, and leverage resources from across the world to continue the development of our unique technology. We are very excited to be working with Johnson & Johnson Innovation on oncolytic therapeutics and look forward to further development."
About ViroGin Biotech Ltd
ViroGin Biotech Ltd is a start-up company formed by a team of scientists with expertise of molecular virology and immunology. The company is located in Vancouver, Canada and Shenzhen, China. ViroGin Biotech is set to develop anti-cancer biological drugs using their novel platform of oncolytic viruses armed with multi-antitumour mechanisms.